Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial-Reference-Cited by-同舟云学术

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Published:2020-03 Issue:3 Volume:15 Page:404-415
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Huber Rudolf M.,Hansen Karin H.,Paz-Ares Rodríguez Luis,West Howard L.,Reckamp Karen L.,Leighl Natasha B.,Tiseo Marcello,Smit Egbert F.,Kim Dong-Wan,Gettinger Scott N.,Hochmair Maximilian J.,Kim Sang-We,Langer Corey J.,Ahn Myung-Ju,Kim Edward S.,Kerstein David,Groen Harry J.M.,Camidge D. Ross

Funder

Ariad Pharmaceuticals

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

2. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

3. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

4. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib;Costa;J Clin Oncol,2011

5. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases;Costa;J Clin Oncol,2015

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

2. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

3. Novel therapeutic strategies for rare mutations in non-small cell lung cancer;Scientific Reports;2024-05-05

4. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer;Clinical Lung Cancer;2024-04

5. Targeted therapeutic options in early and metastatic NSCLC-overview;Pathology and Oncology Research;2024-03-28